Form 8-K - Current report:
SEC Accession No. 0001551152-26-000013
Filing Date
2026-04-29
Accepted
2026-04-29 07:50:28
Documents
14
Period of Report
2026-04-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abbv-20260429.htm   iXBRL 8-K 40034
2 EX-99.1 abbv-20260331xexhibit991.htm EX-99.1 229076
7 abbvieimage1a53.jpg GRAPHIC 15145
  Complete submission text file 0001551152-26-000013.txt   500652

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abbv-20260429.xsd EX-101.SCH 3726
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT abbv-20260429_def.xml EX-101.DEF 19250
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abbv-20260429_lab.xml EX-101.LAB 35029
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abbv-20260429_pre.xml EX-101.PRE 19851
17 EXTRACTED XBRL INSTANCE DOCUMENT abbv-20260429_htm.xml XML 7732
Mailing Address 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064
Business Address 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064 (847) 932-7900
AbbVie Inc. (Filer) CIK: 0001551152 (see all company filings)

EIN.: 320375147 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35565 | Film No.: 26910581
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)